Rishu Agarwal

1.0k total citations · 1 hit paper
18 papers, 444 citations indexed

About

Rishu Agarwal is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Rishu Agarwal has authored 18 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 10 papers in Genetics and 9 papers in Oncology. Recurrent topics in Rishu Agarwal's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Acute Myeloid Leukemia Research (5 papers). Rishu Agarwal is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Acute Myeloid Leukemia Research (5 papers). Rishu Agarwal collaborates with scholars based in Australia, Germany and India. Rishu Agarwal's co-authors include David Westerman, Mark A. Dawson, Sarah‐Jane Dawson, Constantine S. Tam, Martin Dreyling, Stephen Lade, Kate Burbury, Rodney J. Hicks, John F. Seymour and Mathias Bressel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Rishu Agarwal

17 papers receiving 442 citations

Hit Papers

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cel... 2018 2026 2020 2023 2018 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rishu Agarwal Australia 8 314 266 239 92 90 18 444
Simon Husby Denmark 7 258 0.8× 177 0.7× 184 0.8× 57 0.6× 79 0.9× 22 369
Christian Winther Eskelund Denmark 11 432 1.4× 274 1.0× 343 1.4× 51 0.6× 100 1.1× 29 561
Jerry Ping United States 9 249 0.8× 276 1.0× 134 0.6× 44 0.5× 73 0.8× 15 399
Guido Parvis Italy 13 241 0.8× 152 0.6× 197 0.8× 90 1.0× 113 1.3× 27 437
Huiqiang Huang China 8 297 0.9× 149 0.6× 267 1.1× 51 0.6× 100 1.1× 20 460
Karin E. Summers United Kingdom 9 404 1.3× 251 0.9× 280 1.2× 163 1.8× 138 1.5× 11 608
Manfred Welslau Germany 7 335 1.1× 228 0.9× 306 1.3× 55 0.6× 65 0.7× 28 501
Vaishalee P. Kenkre United States 13 258 0.8× 208 0.8× 260 1.1× 78 0.8× 73 0.8× 37 456
Yuqin Song China 10 231 0.7× 202 0.8× 206 0.9× 54 0.6× 111 1.2× 65 443

Countries citing papers authored by Rishu Agarwal

Since Specialization
Citations

This map shows the geographic impact of Rishu Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rishu Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rishu Agarwal more than expected).

Fields of papers citing papers by Rishu Agarwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rishu Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rishu Agarwal. The network helps show where Rishu Agarwal may publish in the future.

Co-authorship network of co-authors of Rishu Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Rishu Agarwal. A scholar is included among the top collaborators of Rishu Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rishu Agarwal. Rishu Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations
2.
3.
Enjeti, Anoop, Rishu Agarwal, Piers Blombery, et al.. (2022). Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology. 54(4). 389–398. 3 indexed citations
4.
5.
Hawkes, Eliza A., Sze Ting Lee, Geoff Chong, et al.. (2021). Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.. Journal of Clinical Oncology. 39(15_suppl). 7560–7560. 3 indexed citations
6.
Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2019). Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood. 134(Supplement_1). 756–756. 25 indexed citations
7.
Barraclough, Allison, Michael Gilbertson, Andrew Grigg, et al.. (2019). Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study. Blood. 134(Supplement_1). 1523–1523. 7 indexed citations
8.
Agarwal, Rishu, Mark A. Dawson, Martin Dreyling, & Constantine S. Tam. (2018). Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leukemia & lymphoma. 59(12). 2769–2781. 14 indexed citations
9.
Tam, Constantine S., Mary Ann Anderson, Christiane Pott, et al.. (2018). Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. New England Journal of Medicine. 378(13). 1211–1223. 274 indexed citations breakdown →
10.
11.
Tam, Constantine S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2017). COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY. Hematological Oncology. 35(S2). 144–145. 3 indexed citations
12.
Tam, Constantine S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2017). Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.. Journal of Clinical Oncology. 35(15_suppl). 7520–7520. 6 indexed citations
13.
Yeh, Paul, Michael Dickinson, Sarah Ftouni, et al.. (2017). Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood. 129(12). 1685–1690. 42 indexed citations
14.
Agarwal, Rishu, Stephen Lade, Danny Liew, et al.. (2015). Role of immunohistochemistry in the era of genetic testing in MYC -positive aggressive B-cell lymphomas: a study of 209 cases. Journal of Clinical Pathology. 69(3). 266–270. 28 indexed citations
15.
Agarwal, Rishu & Surender Juneja. (2013). Pitfalls in the diagnosis of haematological malignancies. 67(2). 39. 3 indexed citations
16.
Agarwal, Rishu, Sreenivas Vishnubhatla, Ritu Gupta, & Sameer Bakhshi. (2011). Diagnostic and Follow-up Eosinophilia Is Not Predictive of Outcome in Childhood Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology. 33(2). e51–e53. 2 indexed citations
17.
Agarwal, Rishu, Ritu Gupta, Sameer Bakhshi, & Atul Sharma. (2010). Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases.. PubMed. 27(1). 43–5. 1 indexed citations
18.
Agarwal, Rishu, et al.. (2008). Synchronous Presentation of Multiple Myeloma and Lung Cancer. Journal of Clinical Oncology. 26(35). 5814–5816. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Husby Breakdown of academic impact, for papers by Christian Winther Eskelund Breakdown of academic impact, for papers by Jerry Ping Breakdown of academic impact, for papers by Guido Parvis Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Karin E. Summers Breakdown of academic impact, for papers by Manfred Welslau Breakdown of academic impact, for papers by Vaishalee P. Kenkre Breakdown of academic impact, for papers by Yuqin Song
Rankless by CCL
2026